Steg PG, James SK, Atar D et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012; 33: 2569-2619.
Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. Eur Heart J, 2012; 33: 2551-2567.
Roe MT, Harrington RA, Prosper DM et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary arterydisease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial investigators. Circulation, 2000; 102: 1101-1106.
Reynolds HR, Srichai MB, Iqbal SN et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation, 2011; 124: 1414-1425.
Larsen AI, Galbraith PD, Ghali WA et al. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol, 2005; 95: 261-263.
Thygesen K, Mair J, Giannitsis E et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J, 2012; 33: 2252-2257.
Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation, 2013; 127: 2452-2457.
Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J, 2014; 35: 552-556.
Reichlin T, Twerenbold R, Maushart C et al. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays. Am Heart J, 2013; 165: 371-378, e373.
Reichlin T, Twerenbold R, Reiter M et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med, 2012; 125: 1205-1213, e1201.
Morrow DA, Cannon CP, Rifai N et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA, 2001; 286: 2405-2412.
Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med, 2006; 166: 1391-1395.
Wallentin L, Lindholm D, Siegbahn A et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2014; 129: 293-303.
Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med, 2013; 368: 2004-2013.
Badimon L, Padro T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care, 2012; 1: 60-74.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med, 2007; 357: 2482-2494.
McManus DD, Gore J, Yarzebski J et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med, 2011; 124: 40-47.
Savonitto S, Ardissino D, Granger CB et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA, 1999; 281: 707-713.
Mandelzweig L, Battler A, Boyko V et al. The Second Euro Heart Survey on Acute Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. Eur Heart J, 2006; 27: 2285-2293.
Terkelsen CJ, Lassen JF, Norgaard BL et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J, 2005; 26: 18-26.
Campeau L. Letter: grading of angina pectoris. Circulation, 1976; 54: 522-523.
Canto JG, Fincher C, Kiefe CI et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol, 2002; 90: 248-253.
Mackay MH, Ratner PA, Johnson JL et al. Gender differences in symptoms of myocardial ischaemia. Eur Heart J, 2011; 32: 3107-3114.
Rubini Gimenez M, Reiter M, Twerenbold R et al. Sex-specific chest pain characteristics in the early diagnosis of acute myocardial infarction. JAMA Intern Med, 2014; 174: 241-249.
Persson A, Hartford M, Herlitz J et al. Long-term prognostic value of mitral regurgitation in acute coronary syndromes. Heart, 2010; 96: 1803-1808.
Grani C, Senn O, Bischof M et al. Diagnostic performance of reproducible chest wall tenderness to rule out acute coronary syndrome in acute chest pain: a prospective diagnostic study. BMJ Open, 2015; 5: e007442.
Devon HA, Rosenfeld A, Steffen AD, Daya M. Sensitivity, specificity, and sex differences in symptoms reported on the 13-item acute coronary syndrome checklist. J Am Heart Assoc, 2014; 3: e000586.
Diercks DB, Peacock WF, Hiestand BC et al. Frequency and consequences of recording an electrocardiogram > 10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). Am J Cardiol, 2006; 97: 437-442.
Okamatsu K, Takano M, Sakai S et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation, 2004; 109: 465-470.
Reichlin T, Hochholzer W, Bassetti S et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med, 2009; 361: 858-867.
Keller T, Zeller T, Peetz D et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med, 2009; 361: 868-877.
Keller T, Zeller T, Ojeda F et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA, 2011; 306: 2684-2693.
Giannitsis E, Becker M, Kurz K et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem, 2010; 56: 642-650.
Haaf P, Drexler B, Reichlin T et al. Highsensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation, 2012; 126: 31-40.
Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem, 2009; 55: 1303-1306.
Rubini Gimenez M, Hoeller R, Reichlin T et al. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardiol, 2013; 168: 3896-3901.
Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J, 2011; 32: 404-411.
Goodacre SW, Bradburn M, Cross E et al. The Randomised Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart, 2011; 97: 190-196.
Reichlin T, Schindler C, Drexler B et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med, 2012; 172: 1211-1218.
Reichlin T, Irfan A, Twerenbold R et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation, 2011; 124: 136-145.
Irfan A, Twerenbold R, Reiter M et al. Determinants of high-sensitivity troponin T among patients with a noncardiac cause of chest pain. Am J Med, 2012; 125: 491-498, e491.
Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2014; 35: 3033-3069, 3069a-3069k.
Erbel R, Aboyans V, Boileau C et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J, 2014; 35: 2873-2926.
Reichlin T, Hochholzer W, Stelzig C et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol, 2009; 54: 60-68.
Keller T, Tzikas S, Zeller T et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol, 2010; 55: 2096-2106.
Raskovalova T, Twerenbold R, Collinson PO et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care, 2014; 3: 18-27.
Lipinski MJ, Escarcega RO, D'Ascenzo F et al. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol, 2014; 113: 1581-1591.
Mockel M, Searle J, Hamm C et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J, 2015; 36: 369-376.
Maisel A, Mueller C, Neath SX et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol, 2013; 62: 150-160.
Balmelli C, Meune C, Twerenbold R et al. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. Am Heart J, 2013; 166: 30-37.
Body R, Carley S, McDowell G et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol, 2011; 58: 1332-1339.
Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol, 2014; 63: 2569-2578.
Zhelev Z, Hyde C, Youngman E et al. Diagnostic accuracy of single baseline measurement of Elecsys troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ, 2015; 350: h15.
Reichlin T, Twerenbold R, Wildi K et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a highsensitivity cardiac troponin T assay. CMAJ, 2015; 187: E243-E252.
Rubini Gimenez M, Twerenbold R, Jaeger C et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. Am J Med, 2015; 128: 861-870. e4.
Than M, Cullen L, Reid CM et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet, 2011; 377: 1077-1084.
Than M, Cullen L, Aldous S et al. 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol, 2012; 59: 2091-2098.
Cullen L, Mueller C, Parsonage WA et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol, 2013; 62: 1242-1249.
Twerenbold R, Wildi K, Jaeger C et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation, 2015; 131: 2041-2050.
Tong KL, Kaul S, Wang XQ et al. Myocardial contrast echocardiography versus thrombolysis in myocardial infarction score in patients presenting to the emergency department with chest pain and a nondiagnostic electrocardiogram. J Am Coll Cardiol, 2005; 46: 920-927.
Grenne B, Eek C, Sjoli B et al. Acute coronary occlusion in non-ST-elevation acute coronary syndrome: outcome and early identification by strain echocardiography. Heart, 2010; 96: 1550-1556.
Lancellotti P, Price S, Edvardsen T et al. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care, 2015; 4: 3-5.
Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J, 2013; 34: 2949-3003.
Shah BN, Balaji G, Alhajiri A et al. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. Circ Cardiovasc Imaging, 2013; 6: 202-209.
Sicari R, Nihoyannopoulos P, Evangelista A et al. Stress echocardiography expert consensus statement - executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J, 2009; 30: 278-289.
Gaibazzi N, Reverberi C, Badano L. Usefulness of contrast stress-echocardiography or exercise-electrocardiography to predict long-term acute coronary syndromes in patients presenting with chest pain without electrocardiographic abnormalities or 12-hour troponin elevation. Am J Cardiol, 2011; 107: 161-167.
Gaibazzi N, Squeri A, Reverberi C et al. Contrast stress-echocardiography predicts cardiac events in patients with suspected acute coronary syndrome but nondiagnostic electrocardiogram and normal 12-hour troponin. J Am Soc Echocardiogr, 2011; 24: 1333-1341.
Ingkanisorn WP, Kwong RY, Bohme NS et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol, 2006; 47: 1427-1432.
Kwong RY, Schussheim AE, Rekhraj S et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 2003;107: 531-537.
Cury RC, Shash K, Nagurney JT et al. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation, 2008; 118: 837-844.
Lockie T, Nagel E, Redwood S, Plein S. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Circulation, 2009; 119: 1671-1681.
Udelson JE, Beshansky JR, Ballin DS et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA, 2002; 288: 2693-2700.
Lim SH, Anantharaman V, Sundram F et al. Stress myocardial perfusion imaging for the evaluation and triage of chest pain in the emergency department: a randomized controlled trial. J Nucl Cardiol, 2013; 20: 1002-1012.
Nabi F, Chang SM, Xu J et al. Assessing risk in acute chest pain: the value of stress myocardial perfusion imaging in patients admitted through the emergency department. J Nucl Cardiol, 2012; 19: 233-243.
Samad Z, Hakeem A, Mahmood SS et al. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol, 2012; 19: 364-376.
Goldstein JA, Gallagher MJ, O'Neill WW et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol, 2007; 49: 863-871.
Goldstein JA, Chinnaiyan KM, Abidov A et al. The CT-STAT (coronary computed tomographic angiography for systematic triage of acute chest pain patients to treatment) trial. J Am Coll Cardiol, 2011; 58: 1414-1422.
Hoffmann U, Truong QA, Schoenfeld DA et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med, 2012; 367: 299-308.
Litt HI, Gatsonis C, Snyder B et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med, 2012; 366: 1393-1403.
Hulten E, Pickett C, Bittencourt MS et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol, 2013; 61: 880-892.
Ayaram D, Bellolio MF, Murad MH et al. Triple rule-out computed tomographic angiography for chest pain: a diagnostic systematic review and meta-analysis. Acad Emerg Med, 2013; 20: 861-871.
Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000; 284: 835-842.
Granger CB, Goldberg RJ, Dabbous O et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med, 2003; 163: 2345-2353.
Fox KA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ, 2006; 333: 1091.
Kaul P, Fu Y, Chang WC et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIB. PARAGON-A and GUSTO IIB Investigators. Platelet IIB/IIIA antagonism for the reduction of acute global organization network. J Am Coll Cardiol, 2001; 38: 64-71.
Mueller C, Neumann FJ, Perach W et al. Prognostic value of the admission electrocardiogram in patients with unstable angina/non-ST-segment elevation myocardial infarction treated with very early revascularization. Am J Med, 2004; 117: 145-150.
Holmvang L, Clemmensen P, Lindahl B et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol, 2003; 41: 905-915.
Tan NS, Goodman SG, Yan RT et al. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. Am Heart J, 2013; 166: 290-297.
Rubini Gimenez M, Twerenbold R, Reichlin T et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J, 2014; 35: 2303-2311.
Haaf P, Reichlin T, Twerenbold R et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J, 2014; 35: 365-375.
Thygesen K, Mair J, Mueller C et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. Eur Heart J, 2012; 33: 2001-2006.
Aragam KG, Tamhane UU, Kline-Rogers E et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS One, 2009; 4: e7947.
de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J, 2005; 26: 865-872.
Fox KA, Fitzgerald G, Puymirat E et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open, 2014; 4: e004425.
Fox KA, Anderson FA Jr, Dabbous OH et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart, 2007; 93: 177-182.
Bawamia B, Mehran R, Qiu W, Kunadian V. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am Heart J, 2013; 165: 441-450.
Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol, 2010; 55: 1403-1415.
Chang WC, Boersma E, Granger CB et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIB and PURSUIT. Am Heart J, 2004; 148: 62-71.
Rahimi K, Watzlawek S, Thiele H et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J, 2006; 27: 1706-1711.
Piccini JP, White JA, Mehta RH et al. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation, 2012; 126: 41-49.
Drew BJ, Califf RM, Funk M et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation, 2004; 110: 2721-2746.
Dressler R, Dryer MM, Coletti C et al. Altering overuse of cardiac telemetry in non-intensive care unit settings by hardwiring the use of American Heart Association guidelines. JAMA Intern Med, 2014; 174: 1852-1854.
Fox KA, Anderson FA Jr, Goodman SG et al. Time course of events in acute coronary syndromes: implications for clinical practice from the grace registry. Nat Clin Pract Cardiovasc Med, 2008; 5: 580-589.
Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol, 2010; 55: 2556-2566.
Steg PG, Huber K, Andreotti F et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology. Eur Heart J, 2011; 32: 1854-1864.
Subherwal S, Bach RG, Chen AY et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation, 2009; 119: 1873-1882.
Abu-Assi E, Raposeiras-Roubin S, Lear P et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care, 2012; 1: 222-231.
Weber M, Bazzino O, Navarro Estrada JL et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J, 2011; 162: 81-88.
Akkerhuis KM, Klootwijk PA, Lindeboom W et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J, 2001; 22: 1997-2006.
Hamm CW, Goldmann BU, Heeschen C et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med, 1997; 337: 1648-1653.
Antman EM, Tanasijevic MJ, Thompson B et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med, 1996; 335: 1342-1349.
Scirica BM, Morrow DA, Budaj A et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLINTIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36) trial. J Am Coll Cardiol, 2009; 53: 1411-1421.
Nyman I, Wallentin L, Areskog M et al. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC study group. Int J Cardiol, 1993; 39: 131-142.
Amsterdam EA, Kirk JD, Diercks DB et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol, 2002; 40: 251-256.
Stub D, Smith K, Bernard S et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation, 2015; 131: 2143-2150.
Borzak S, Cannon CP, Kraft PL et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin inhibition in myocardial ischemia. Am J Cardiol, 1998; 81: 678-681.
Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation, 2010; 122: 88-95.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA, 1988; 260: 2088-2093.
Chatterjee S, Chaudhuri D, Vedanthan R et al. Early intravenous beta-blockers in patients with acute coronary syndrome - a meta-analysis of randomized trials. Int J Cardiol, 2013; 168: 915-921.
Kontos MC, Diercks DB, Ho PM et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blockertherapy: results from the American College of Cardiology's NCDRw. Am Heart J, 2011; 161: 864-870.
Theroux P, Taeymans Y, Morissette D et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol, 1985; 5: 717-722.
Parodi O, Simonetti I, Michelassi C et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. Am J Cardiol, 1986; 57: 899-906.
Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT). Am J Cardiol, 1987; 60: 18A-25A.
Hansen JF. Treatment with verapamil after an acute myocardial infarction. Review of the Danish Studies on Verapamil in Myocardial Infarction (DAVIT I and II). Drugs, 1991; 42 (suppl. 2): 43-53.
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA, 2007; 297: 1775-1783.
Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med, 2007; 120: 685-692.
Yasue H, Takizawa A, Nagao M et al. Long-term prognosis for patients with variant angina and influential factors. Circulation, 1988; 78: 1-9.
Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J, 2011; 32: 2922-2932.
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC group. Lancet, 1990; 336: 827-830.
Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med, 1983; 309: 396-403.
Theroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med, 1988; 319: 1105-1111.
Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med, 1985; 313: 1369-1375.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.
Mehta SR, Bassand JP, Chrolavicius S et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med, 2010; 363: 930-942.
Savi P, Labouret C, Delesque N et al. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun, 2001; 283: 379-383.
Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost, 2005; 31: 174-183.
Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494-502.
Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001; 358: 527-533.
Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 2011; 306: 1215-1223.
Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004; 109: 3171-3175.
Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol, 2006; 48: 1742-1750.
Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol, 2009; 53: 849-856.
Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2014; 35: 209-215.
Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009; 360: 363-375.
Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, 2009; 373: 309-317.
Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol, 2010; 56: 112-116.
Cayla G, Hulot JS, O'Connor SA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA, 2011; 306: 1765-1774.
Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007; 357: 2001-2015.
De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care, 2014; 3: 363-372.
Pena A, Collet JP, Hulot JS et al. Can we override clopidogrel resistance? Circulation, 2009; 119: 2854-2857.
Wiviott SD, Braunwald E, McCabe CH et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet, 2008; 371: 1353-1363.
Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the Onset/Offset study. Circulation, 2009; 120: 2577-2585.
Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361: 1045-1057.
Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J, 2014; 35: 2083-2093.
Steg PG, Harrington RA, Emanuelsson H et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation, 2013; 128: 1055-1065.
Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J, 2011; 32: 2945-2953.
Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2 T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost, 2001; 85: 401-407.
Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med, 2009; 361: 2318-2329.
Bhatt DL, Lincoff AM, Gibson CM et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med, 2009; 361: 2330-2341.
Bhatt DL, Stone GW, Mahaffey KW et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med, 2013; 368: 1303-1313.
Steg PG, Bhatt DL, Hamm CW et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, 2013; 382: 1981-1992.
Hamm CW, Bassand JP, Agewall S et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 2999-3054.
Bellemain-Appaix A, Brieger D, Beygui F et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol, 2010; 56: 1542-1551.
Montalescot G, Bolognese L, Dudek D et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med, 2013; 369: 999-1010.
Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation, 2014; 130: 1904-1914.
Valgimigli M. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. Circulation, 2014; 130: 1891-1903.
Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013; 382: 614-623.
Price MJ, Berger PB, Teirstein PS et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011; 305: 1097-1105.
Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol, 2012; 59: 2159-2164.
Collet JP, Cuisset T, Range G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med, 2012; 367: 2100-2109.
Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet, 2010; 376: 1312-1319.
Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol, 2008; 51: 1925-1934.
Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009; 119: 2553-2560.
Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet, 2012; 379: 1705-1711.
Agewall S, Cattaneo M, Collet JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J, 2013; 34: 1708-1713, 1713a-1713b.
Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med, 2006; 166: 1842-1847.
Mehran R, Baber U, Steg PG et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, 2013; 382: 1714-1722.
Grines CL, Bonow RO, Casey DE Jr et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 2007; 115: 813-818.
Kristensen SD, Knuuti J, Saraste A et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J, 2014; 35: 2383-2431.
Dunning J, Versteegh M, Fabbri A et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg, 2008; 34: 73-92.
Savonitto S, D'Urbano M, Caracciolo M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth, 2010; 104: 285-291.
Angiolillo DJ, Firstenberg MS, Price MJ et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA, 2012; 307: 265-274.
Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002; 288: 2411-2420.
Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 2014; 371: 2155-2166.
Navarese EP, Andreotti F, Schulze V et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 2015; 350: h1618.
Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015; 372: 1791-1800.
Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol, 2012; 60: 1340-1348.
Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA, 2013; 310: 2510-2522.
Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation, 2012; 125: 505-513.
Valgimigli M, Campo G, Monti M et al. Shortversus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation, 2012; 125: 2015-2026.
Colombo A, Chieffo A, Frasheri A et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol, 2014; 64: 2086-2097.
Schulz-Schupke S, Byrne RA, ten Berg JM et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J, 2015; 36: 1252-1263.
Gilard M, Barragan P, Noryani AA et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol, 2015; 65: 777-786.
Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation, 2014; 129: 304-312.
Collet JP, Silvain J, Barthelemy O et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-INTERRUPTION): a randomised trial. Lancet, 2014; 384: 1577-1585.
Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J, 2002; 23: 1441-1448.
O'Donoghue M, Antman EM, Braunwald E et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) analysis. J Am Coll Cardiol, 2009; 54: 678-685.
Stone GW, Bertrand ME, Moses JW et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA, 2007; 297: 591-602.
Giugliano RP, White JA, Bode C et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med, 2009; 360: 2176-2190.
Wang TY, White JA, Tricoci P et al. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysisfrom the early glycoprotein IIb/IIIa inhibition in patients with non-ST-segment elevation acute coronary syndrome (early ACS) trial. Circulation, 2011; 123: 722-730.
Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40 l release and procoagulant responses. Platelets, 2005; 16: 398-407.
Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISARREACT 2 randomized trial. JAMA, 2006; 295: 1531-1538.
Jolly SS, Faxon DP, Fox KA et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol, 2009; 54: 468-476.
White HD, Chew DP, Hoekstra JW et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 2008; 51: 1734-1741.
Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med, 2006; 355: 2203-2216.
Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med, 2012; 366: 20-33.
Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med, 2012; 366: 1404-1413.
Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010; 363: 1909-1917.
Eikelboom JW, Anand SS, Malmberg K et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet, 2000; 355: 1936-1942.
Silvain J, Beygui F, Barthelemy O et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ, 2012; 344: e553.
Lee MS, Wali AU, Menon V et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis, 2002; 14: 91-101.
Hassan WM, Flaker GC, Feutz C et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis, 1995; 2: 245-249.
Collet JP, Montalescot G, Lison L et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation, 2001; 103: 658-663.
Martin JL, Fry ET, Sanderink GJ et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv, 2004; 61: 163-170.
Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-riskpatients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA, 2004; 292: 45-54.
Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J, 2007; 28: 2077-2086.
Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 2006; 354: 1464-1476.
Steg PG, Jolly SS, Mehta SR et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA, 2010; 304: 1339-1349.
Szummer K, Oldgren J, Lindhagen L et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA, 2015; 313: 707-716.
Stone GW, White HD, Ohman EM et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Lancet, 2007; 369: 907-919.
Stone GW, Ware JH, Bertrand ME et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA, 2007; 298: 2497-2506.
Kastrati A, Neumann FJ, Schulz S et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med, 2011; 365: 1980-1989.
Kastrati A, Neumann FJ, Mehilli J et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med, 2008; 359: 688-696.
Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med, 2011; 365: 699-708.
Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 366: 9-19.
Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA, 1996; 276: 811-815.
Simoons ML, Bobbink IW, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) study. J Am Coll Cardiol, 2004; 43: 2183-2190.
Mehta SR, Steg PG, Granger CB et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. Circulation, 2005; 111: 1390-1397.
Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA, 2004; 292: 89-96.
Brener SJ, Moliterno DJ, Lincoff AM et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation, 2004; 110: 994-998.
Gilard M, Blanchard D, Helft G et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTing and oral antiCOagulants [STENTICO]). Am J Cardiol, 2009; 104: 338-342.
Ruiz-Nodar JM, Marin F, Hurtado JA et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol, 2008; 51: 818-825.
Lip GY, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology working group on thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J, 2014; 35: 3155-3179.
Beyer-Westendorf J, Gelbricht V, Forster K et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J, 2014; 35: 1888-1896.
Dewilde WJ, Janssen PW, Kelder JC et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention, 2015 Mar 5; 10(11). pii: 20140202-08. doi:10.4244/EIJY14M06-07. [Epub ahead of print].
Kiviniemi T, Karjalainen P, Pietila M et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2012; 110: 30-35.
Hansen ML, Sorensen R, Clausen MT et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010; 170: 1433-1441.
Faxon DP, Eikelboom JW, Berger PB et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv, 2011; 4: 522-534.
Stettler C, Allemann S, Wandel S et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ, 2008; 337: a1331.
Bangalore S, Kumar S, Fusaro M et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ, 2012; 345: e5170.
Bangalore S, Kumar S, Fusaro M et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation, 2012; 125: 2873-2891.
Kereiakes DJ, Yeh RW, Massaro JM et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA, 2015; 313: 1113-1121.
Hawn MT, Graham LA, Richman JS et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA, 2013; 310: 1462-1472.
Valgimigli M, Patialiakas A, Thury A et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol, 2015; 65: 805-815.
Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet, 2013; 381: 1107-1115.
Fiedler KA, Maeng M, Mehilli J et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol, 2015; 65: 1619-1629.
Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation, 2012; 126: 1185-1193.
Lamberts M, Gislason GH, Olesen JB et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol, 2013; 62: 981-989.
Sie P, Samama CM, Godier A et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis, 2011; 104: 669-676.
Valgimigli M, Gagnor A, Calabro P et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, 2015; 385: 2465-2476.
Bangalore S, Toklu B, Amoroso N et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ, 2013; 347: f6625.
Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood, 1983; 61: 1081-1085.
Vilahur G, Choi BG, Zafar MU et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost, 2007; 5: 82-90.
Hansson EC, Shams Hakimi C, Astrom-Olsson K et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth, 2014; 112: 570-575.
Zafar MU, Santos-Gallego C, Vorchheimer DA et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost, 2013; 11: 100-106.
Patel RJ, Witt DM, Saseen JJ et al. Randomized, placebocontrolled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy, 2000; 20: 1159-1166.
Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis, 2001; 12: 9-16.
Ageno W, Crowther M, Steidl L et al. Low dose oral vitamin K to reverse acenocoumarolinduced coagulopathy: a randomized controlled trial. Thromb Haemost, 2002; 88: 48-51.
Ageno W, Garcia D, Silingardi M et al. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol, 2005; 46: 732-733.
Crowther MA, Ageno W, Garcia D et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med, 2009; 150: 293-300.
Crowther MA, Julian J, McCarty D et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet, 2000; 356: 1551-1553.
Ageno W, Garcia D, Aguilar MI et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol, 2009; 84: 584-588.
Ageno W, Gallus AS, Wittkowsky A et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141: e44S-88S.
Liesenfeld KH, Staab A, Hartter S et al. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet, 2013; 52: 453-462.
Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 2011; 124: 1573-1579.
Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 2013; 19: 446-451.
Verheugt FW, Steinhubl SR, Hamon M et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv, 2011; 4: 191-197.
Ndrepepa G, Schulz S, Neumann FJ et al. Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. Am Heart J, 2013; 166: 534-540.
Vranckx P, Campo G, Anselmi M et al. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention, 2012; 8: 71-78.
Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J, 2011; 32: 2933-2944.
Lopes RD, Subherwal S, Holmes DN et al. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J, 2012; 33: 2044-2053.
Mehran R, Rao SV, Bhatt DL et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation, 2011; 123: 2736-2747.
Ndrepepa G, Schuster T, Hadamitzky M et al. Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation, 2012; 125: 1424-1431.
Ndrepepa G, Guerra E, Schulz S et al. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. J Thromb Thrombolysis, 2015; 39: 35-42.
Baber U, Kovacic J, Kini AS et al. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep, 2011; 13: 312-319.
Ndrepepa G, Berger PB, Mehilli J et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol, 2008; 51: 690-697.
Moscucci M, Fox KA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J, 2003; 24: 1815-1823.
Leibundgut G, Pache J, Schulz S et al. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non ST-segment elevation myocardial infarction. J Interv Cardiol, 2013 26: 623-629.
Ndrepepa G, Neumann FJ, Richardt G et al. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv, 2013; 6: 354-361.
Marso SP, Amin AP, House JA et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA, 2010; 303: 2156-2164.
Schulz-Schupke S, Helde S, Gewalt S et al. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. JAMA, 2014; 312: 1981-1987.
Shi J, Ji H, Ren F et al. Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. JAMA Surg, 2013; 148: 538-547.
Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (PLATelet inhibition and patient Outcomes) trial. J Am Coll Cardiol, 2011; 57: 672-684.
Mehta RH, Sheng S, O'Brien SM et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes, 2009; 2: 583-590.
Paone G, Likosky DS, Brewer R et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. Ann Thorac Surg, 2014; 97: 87-93; discussion 93-84.
Ferraris VA, Saha SP, Oestreich JH et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg, 2012; 94: 1761-1781.
Vivacqua A, Koch CG, Yousuf AM et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg, 2011; 91: 1780-1790.
Hardy JF, Belisle S, Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Curr Opin Anaesthesiol, 2009; 22: 95-99.
Lamy A, Devereaux PJ, Prabhakaran D et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med, 2012; 366: 1489-1497.
Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA, 2004; 292: 1555-1562.
Sherwood MW, Wang Y, Curtis JP et al. Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. JAMA, 2014; 311: 836-843.
Nikolsky E, Mehran R, Sadeghi HM et al. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. JACC Cardiovasc Interv, 2009; 2: 624-632.
Silvain J, Abtan J, Kerneis M et al. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry). J Am Coll Cardiol, 2014; 63: 1289-1296.
Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev, 2012; 4: CD002042.
Kansagara D, Dyer E, Englander H et al. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med, 2013; 159: 746-757.
Chatterjee S, Wetterslev J, Sharma A et al. Association of blood transfusion with increased mortality in myocardial infarction: ameta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med, 2013; 173: 132-139.
Cooper HA, Rao SV, Greenberg MD et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). Am J Cardiol, 2011; 108: 1108-1111.
Alexander KP, Chen AY, Wang TY et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J, 2008; 155: 1047-1053.
Holst LB, Petersen MW, Haase N et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomized trials with meta-analysis and trial sequential analysis. BMJ, 2015; 350: h1354.
Murphy GJ, Pike K, Rogers CA et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med, 2015; 372: 997-1008.
Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med, 2009; 360: 2165-2175.
Thiele H, Rach J, Klein N et al. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig immediate versus early and late PercutaneouS coronary intervention triAl in NSTEMI (LIPSIA-NSTEMI trial). Eur Heart J, 2012; 33: 2035-2043.
Ndrepepa G, Mehilli J, Schulz S et al. Patterns of presentation and outcomes of patients with acute coronary syndromes. Cardiology, 2009; 113: 198-206.
Kerensky RA, Wade M, Deedwania P et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol, 2002; 39: 1456-1463
Ambrose JA, Winters SL, Stern A et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol, 1985; 5 :609-616.
Goldstein JA, Demetriou D, Grines CL et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med, 2000; 343: 915-922.
Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012; 32: 2045-2051.
Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol, 2006; 47: C13-C18.
Vergallo R, Ren X, Yonetsu T et al. Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. Am Heart J, 2014; 167: 59-67.
Cheruvu PK, Finn AV, Gardner C et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol, 2007; 50: 940-949.
Shishehbor MH, Lauer MS, Singh IM et al. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culpritonly stenting? J Am Coll Cardiol, 2007; 49: 849-854.
Sgarbossa EB, Birnbaum Y, Parrillo JE. Electrocardiographic diagnosis of acute myocardial infarction: current concepts for the clinician. Am Heart J, 2001; 141: 507-517.
Kurisu S, Inoue I, Kawagoe T et al. Electrocardiographic features in patients with acute myocardial infarction associated with left main coronary artery occlusion. Heart, 2004; 90: 1059-1060.
de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA. A new ECG sign of proximal LAD occlusion. N Engl J Med, 2008; 359: 2071-2073.
Tahvanainen M, Nikus KC, Holmvang L et al. Factors associated with failure to identify the culprit artery by the electrocardiogram in inferior ST-elevation myocardial infarction. J Electrocardiol, 2011; 44: 495-501.
Tanaka A, Shimada K, Tearney GJ et al. Conformational change in coronary artery structure assessed by optical coherence tomography in patients with vasospastic angina. J Am Coll Cardiol, 2011; 58: 1608-1613.
Kato M, Dote K, Sasaki S et al. Presentations of acute coronary syndrome related tocoronary lesion morphologies as assessed by intravascular ultrasound and optical coherence tomography. Int J Cardiol, 2013; 165: 506-511.
Pijls NH, Tanaka N, Fearon WF. Functional assessment of coronary stenoses: can we live without it? Eur Heart J, 2013; 34: 1335-1344.
Gersh BJ, Frye RL. Methods of coronary revascularization - things may not be as they seem. N Engl J Med, 2005; 352: 2235-2237.
Bavry AA, Kumbhani DJ, Rassi AN et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol, 2006; 48: 1319-1325.
O'Donoghue M, Boden WE, Braunwald E et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA, 2008; 300: 71-80.
Fox KA, Clayton TC, Damman P et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol, 2010; 55: 2435-2445.
Noc M, Fajadet J, Lassen JF et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent For Life (SFL) groups. Euro Intervention, 2014; 10: 31-37.
Katritsis DG, Siontis GC, Kastrati A et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J, 2011; 32: 32-40.
Navarese EP, Gurbel PA, Andreotti F et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med, 2013; 158: 261-270.
Riezebos RK, Ronner E, Ter Bals E et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart, 2009; 95: 807-812.
Montalescot G, Cayla G, Collet JP et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA, 2009; 302: 947-954.
Sorajja P, Gersh BJ, Cox DA et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 2010; 55: 1416-1424.
Amsterdam EA, Kirk JD, Bluemke DA et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation, 2010; 122: 1756-1776.
De Ferrari GM, Fox KA, White JA et al. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care, 2014; 3: 37-45.
Solomon MD, Go AS, Shilane D et al. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol, 2014; 63: 2249-2257.
Roe MT, Armstrong PW, Fox KA et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med, 2012; 367: 1297-1309.
James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 2011; 342: d3527.
Williams B, Menon M, Satran D et al. Patients with coronary artery disease notamenable to traditional revascularization: prevalence and 3-year mortality. Cathet Cardiovasc Interv, 2010; 75: 886-891.
Henry TD, Satran D, Hodges JS et al. Long-term survival in patients with refractory angina. Eur Heart J, 2013; 34: 2683-2688.
Bellandi B, Salvadori C, Parodi G et al. Epidemiology of Tako-Tsubo cardiomyopathy: the Tuscany registry for Tako-Tsubo cardiomyopathy. G Ital Cardiol (Rome), 2012; 13: 59-66.
Sy F, Basraon J, Zheng H et al. Frequency of takotsubo cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome. Am J Cardiol, 2013; 112: 479-482.
Jaguszewski M, Osipova J, Ghadri JR et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J, 2014; 35: 999-1006.
Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. Herz, 2010; 35: 240-243.
Ong P, Athanasiadis A, Hill S et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (Coronary Artery Spasm in Patients with Acute coRonary syndrome) study. J Am Coll Cardiol, 2008; 52: 523-527.
Mohri M, Koyanagi M, Egashira K et al. Angina pectoris caused by coronary microvascular spasm. Lancet, 1998; 351: 1165-1169.
Raber L, Kelbaek H, Ostojic M et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA, 2012; 308: 777-787.
Sabate M, Cequier A, Iniguez A et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (examination): 1 year results of a randomised controlled trial. Lancet, 2012; 380: 1482-1490.
Valgimigli M, Tebaldi M, Borghesi M et al. Two year outcomes after first-or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study). JACC Cardiovasc Interv, 2014; 7: 20-28.
Lagerqvist B, Frobert O, Olivecrona GK et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med, 2014; 371: 1111-1120.
Jolly SS, Yusuf S, Cairns J et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, 2011; 377: 1409-1420.
Rao SV, Hess CN, Barham B et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv, 2014; 7: 857-867.
Hamon M, Pristipino C, Di Mario C et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and working groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention, 2013; 8: 1242-1251.
Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med, 2001; 344: 1879-1887.
Fox KA, Poole-Wilson PA, Henderson RA et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. Lancet, 2002; 360: 743-751.
Wallentin L, Lagerqvist B, Husted S et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet, 2000; 356: 9-16.
Farooq V, Serruys PW, Bourantas CV et al. Quantification of incomplete revascularization and its association with five-year mortality in the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation, 2013; 128: 141-151.
Genereux P, Palmerini T, Caixeta A et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (SYNergy between PCI with TAXus and cardiac surgery) score. J Am Coll Cardiol, 2012; 59: 2165-2174.
Curtis JP, Schreiner G, Wang Y et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of Medicare patients. J Am Coll Cardiol, 2009; 54: 903-907.
Meadows ES, Bae JP, Zagar A et al. Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis. BMC Res Notes, 2012; 5: 342.
Ranasinghe I, Alprandi-Costa B, Chow V et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol, 2011; 108: 617-624.
Martensson S, Gyrd-Hansen D, Prescott E et al. Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. BMJ Open, 2014; 4: e004052.
Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg, 2013; 145: 1577-1583, e1571.
Weiss ES, Chang DD, Joyce DL et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. J Thorac Cardiovasc Surg, 2008;135: 503-511, e501-503.
Deyell MW, Ghali WA, Ross DB, et al. Timing of nonemergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome. Am Heart J, 2010; 159: 490-496.
Parikh SV, de Lemos JA, Jessen ME et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv, 2010; 3: 419-427.
Lim E, Ali Z, Ali A et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ, 2003; 327: 1309.
Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation, 1991; 83: 1526-1533.
Biondi-Zoccai GG, Lotrionte M, Agostoni P et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J, 2006; 27: 2667-2674.
Sun JC, Whitlock R, Cheng J et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J, 2008; 29: 1057-1071.
Deja MA, Kargul T, Domaradzki W et al. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg, 2012; 144: 204-209.
Biancari F, Airaksinen KE, Lip GY. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg, 2012; 143: 665-675, e664.
Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J, 2011; 32: 2970-2988.
Mahla E, Suarez TA, Bliden KP et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGETCABG) study. Circulation Cardiovasc Interv, 2012; 5: 261-269.
Rastan AJ, Eckenstein JI, Hentschel B et al. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. Circulation, 2006; 114: I477-485.
Ben-Gal Y, Moses JW, Mehran R et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv, 2010; 3: 1059-1067.
Harling L, Moscarelli M, Kidher E et al. The effect of off-pump coronary artery bypass on mortality after acute coronary syndrome: a meta-analysis. Int J Cardiol, 2013; 169: 339-348.
Stamou SC, Hill PC, Haile E et al. Clinical outcomes of nonelective coronary revascularization with and without cardiopulmonary bypass. J Thorac Cardiovasc Surg, 2006; 131: 28-33.
Hlatky MA, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, 2009; 373: 1190-1197.
Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, 2013; 381: 629-638.
Farkouh ME, Domanski M, Sleeper LA et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med, 2012; 367: 2375-2384.
Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J, 2014; 35: 2541-2619.
Palmerini T, Genereux P, Caixeta A et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 2011; 57: 2389-2397.
Hasdai D, Harrington RA, Hochman JS et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol, 2000; 36: 685-692.
Holmes DR Jr., Berger PB, Hochman JS et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation, 1999; 100: 2067-2073.
Thiele H, Zeymer U, Neumann FJ et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med, 2012; 367: 1287-1296.
Stefanini GG, Baber U, Windecker S et al. Safetyand efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomized trials. Lancet, 2013; 382: 1879-1888.
Kaiser C, Galatius S, Erne P et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med, 2010; 363: 2310-2319.
Greenhalgh J, Hockenhull J, Rao N et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev, 2010; 5: CD004587.
Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation, 2009; 119: 3198-3206.
Moses JW, Mehran R, Nikolsky E et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol, 2005; 45: 1165-1171.
Yan AT, Yan RT, Tan M et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med, 2007; 167: 1009-1016.
Poon S, Goodman SG, Yan RT et al. Bridging the gender gap: insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J, 2012; 163: 66-73.
Canto JG, Rogers WJ, Goldberg RJ et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA, 2012; 307: 813-822.
Mehilli J, Kastrati A, Dirschinger J et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. JAMA, 2002; 287: 210-215.
Alfredsson J, Lindback J, Wallentin L, Swahn E. Similar outcome with an invasive strategy in men and women with non-ST-elevation acute coronary syndromes: from the Swedish Web-system for Enhancement and Development of Evidencebased care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Eur Heart J, 2011; 32: 3128-3136.
Chew DP, Juergens C, French J et al. An examination of clinical intuition in risk assessment among acute coronary syndromes patients: observations from a prospective multi-center international observational registry. Int J Cardiol, 2014; 171: 209-216.
Gore MO, Seliger SL, Defilippi CR et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol, 2014; 63: 1441-1448.
Dey S, Flather MD, Devlin G et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart, 2009; 95: 20-26.
Hochman JS, Tamis JE, Thompson TD et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med, 1999; 341:226-232.
Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation, 2004; 109: 580-586.
Terkelsen CJ, Sorensen JT, Maeng M et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA, 2010; 304: 763-771.
Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation, 2006;114: 1380-1387.
Jneid H, Fonarow GC, Cannon CP et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation, 2008; 118: 2803-2810.
Vaccarino V, Parsons L, Peterson ED et al. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. Arch Intern Med, 2009; 169: 1767-1774.
Mehilli J, Kastrati A, Bollwein H et al. Gender and restenosis after coronary artery stenting. Eur Heart J, 2003; 24: 1523-1530.
Blomkalns AL, Chen AY, Hochman JS et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines) national quality improvement initiative. J Am Coll Cardiol, 2005; 45: 832-837.
Gale CP, Cattle BA, Woolston A et al. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The myocardial ischaemia national audit project 2003-2010. Eur Heart J, 2012; 33: 630-639.
Bauer T, Koeth O, Junger C et al. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction. Eur Heart J, 2007; 28: 2873-2878.
Alexander KP, Newby LK, Cannon CP et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation, 2007; 115: 2549-2569.
Rosengren A, Wallentin L, Simoons M et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J, 2006; 27: 789-795.
Brieger D, Eagle KA, Goodman SG et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the global registry of acute coronary events. Chest, 2004; 126: 461-469.
Reiter M, Twerenbold R, Reichlin T et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J, 2011; 32: 1379-1389.
Fox KA, Eagle KA, Gore JM et al. The global registry of acute coronary events, 1999 to 2009 - GRACE. Heart, 2010; 96: 1095-1101.
Skolnick AH, Alexander KP, Chen AY et al. Characteristics, management, and outcomes of 5,557 patients age ≥ 90 years with acute coronary syndromes: results from the CRUSADE initiative. J Am Coll Cardiol, 2007; 49: 1790-1797.
Devlin G, Gore JM, Elliott J et al. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Eur Heart J, 2008; 29: 1275-1282.
Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry. BMJ Open, 2012; 2: e000540.
Bach RG, Cannon CP, Weintraub WS et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med, 2004; 141: 186-195.
Savonitto S, Cavallini C, Petronio AS et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv, 2012; 5: 906-916.
Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA, 2005; 294: 3108-3116.
Afilalo J, Alexander KP, Mack MJ et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol, 2014; 63: 747-62.
Ekerstad N, Swahn E, Janzon M et al. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation, 2011; 124: 2397-2404.
Giraldez RR, Clare RM, Lopes RD et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J, 2013; 165: 918-925, e912.
Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol, 2005; 96: 363-365.
Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002; 359: 2140-2144.
Bartnik M, Ryden L, Malmberg K et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart, 2007; 93: 72-77.
Dotevall A, Hasdai D, Wallentin L et al. Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS. Diabet Med, 2005; 22: 1542-1550.
Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA, 2007; 298: 765-775.
Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care, 2009; 32: 531-540.
Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation, 2011; 123: 798-813.
Bartnik M, Malmberg K, Norhammar A et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J, 2004; 25: 1990-1997.
De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J, 2010; 31: 1557-1564.
Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J, 2005; 26: 1255-1261.
Ryden L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J, 2013; 34: 3035-3087.
Verges B, Avignon A, Bonnet F et al. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab, 2012; 38: 113-127.
Kappetein AP, Head SJ, Morice MC et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg, 2013; 43: 1006-1013.
Kapur A, Hall RJ, Malik IS et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDIA (Coronary Artery Revascularization in DIAbetes) trial. J Am Coll Cardiol, 2010; 55: 432-440.
Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J, 2011; 32: 2748-2757.
Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeuticoutcomes by optimizing platelet inhibition with prasugrel-Thrombolysis In Myocardial Infarction 38. Circulation, 2008; 118: 1626-1636.
James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J, 2010; 31: 3006-3016.
Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation, 2001; 104: 2767-2771.
O'Donoghue ML, Vaidya A, Afsal R et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol, 2012; 60: 106-111.
Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2004; 25: 190-198.
Daemen J, Garcia-Garcia HM, Kukreja N et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J, 2007; 28: 26-32.
Verma S, Farkouh ME, Yanagawa B et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol, 2013; 1: 317-328.
Hakeem A, Garg N, Bhatti S et al. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc, 2013; 2: e000354.
Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol, 2004; 44: 1587-1592.
Szummer K, Lundman P, Jacobson SH et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med, 2010; 268: 40-49.
Szummer K, Lundman P, Jacobson SH et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation, 2009; 120: 851-858.
James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation, 2010; 122: 1056-1067.
Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs, 2005; 5: 291-305.
Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation, 2012; 125: 2649-2661.
Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol, 2010; 70: 703-712.
Collet JP, Montalescot G, Agnelli G et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J, 2005; 26: 2285-2293.
Fox KA, Bassand JP, Mehta SR et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med, 2007; 147: 304-310.
Brar SS, Shen AY, Jorgensen MB et al. Sodium bicarbonate vs sodium chloride for the preventionof contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA, 2008; 300: 1038-1046.
Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA, 2004; 291: 2328-2334.
Jo SH, Youn TJ, Koo BK et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol, 2006; 48: 924-930.
Maioli M, Toso A, Leoncini M et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv, 2011; 4: 456-462.
Aspelin P, Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med, 2003; 348: 491-499.
Solomon RJ, Natarajan MK, Doucet S et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation, 2007; 115: 3189-3196.
Tsai TT, Messenger JC, Brennan JM et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol, 2011; 58: 1859-1869.
Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS One, 2010; 5: e15070.
Chang TI, Shilane D, Kazi DS et al. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol, 2012; 23: 2042-2049.
Zheng H, Xue S, Lian F et al. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg, 2013; 43: 459-467.
Fox CS, Muntner P, Chen AY et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation, 2010; 121: 357-365.
Yan LQ, Guo LJ, Zhang FC, Gao W. The relationship between kidney function and angiographically-derived SYNTAX score. Can J Cardiol, 2011; 27: 768-772.
Steg PG, Dabbous OH, Feldman LJ et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation, 2004; 109: 494-499.
Roger VL. Epidemiology of heart failure. Circ Res, 2013; 113: 646-659.
McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J, 2012; 33: 1787-1847.
Thiele H, Zeymer U, Neumann FJ et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet, 2013; 382: 1638-1645.
Kirklin JK, Naftel DC, Kormos RL et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant, 2012; 31: 117-126.
Kirklin JK. Long-term mechanical circulatory support: could it really have a public health impact? Eur J Cardiothorac Surg, 2013; 44: 198-200.
Kirklin JK, Naftel DC, Pagani FD et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg, 2012; 144: 584-603; discussion 597-588.
McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014; 371: 993-1004.
Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med, 1999; 341: 625-634.
Hochman JS, Sleeper LA, Webb JG et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA, 2006; 295: 2511-2515.
Buerke M, Prondzinsky R, Lemm H et al. Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock - review of the current evidence. Artif Organs, 2012; 36: 505-511.
Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med, 1992; 327: 669-677.
Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003; 349: 1893-1906.
Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003; 362: 772-776.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med, 1991; 325: 293-302.
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001; 357: 1385-1390.
CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet, 1999; 353: 9-13.
Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651-1658.
MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet, 1999; 353: 2001-2007.
Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 2005; 26: 215-225.
Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21.
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med, 1999; 341: 709-717.
Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002; 346: 877-883.
Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005; 352: 225-237.
Al-Khatib SM, Hellkamp AS, Lee KL et al. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in HEart Failure Trial (SCD-HEFT). J Cardiovasc Electrophysiol, 2008; 19: 1059-1065.
Barsheshet A, Goldenberg I, Moss AJ et al. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial. J Cardiovasc Electrophysiol, 2011; 22: 1237-1242.
Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrialfibrillation - developed with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012; 33: 2719-2747.
Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31: 2369-2429.
Lippi G, Picanza A, Formentini A et al. The concentration of troponin I is increased in patients with acute-onset atrial fibrillation. Int J Cardiol, 2014; 173: 579-580.
Hijazi Z, Siegbahn A, Andersson U et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation, 2014; 129: 625-634.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med, 1999; 131: 492-501.
Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med, 1991; 324 781-788.
Younge JO, Nauta ST, Akkerhuis KM et al. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. Am J Cardiol, 2012; 109: 506-510.
Bassand JP, Afzal R, Eikelboom J et al. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J, 2010; 31: 50-58.
Chase AJ, Fretz EB, Warburton WP et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart, 2008; 94: 1019-1025.
Agostoni P, Biondi-Zoccai GG, de Benedictis ML et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol, 2004; 44: 349-356.
McClure MW, Berkowitz SD, Sparapani R et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience. Circulation, 1999; 99: 2892-2900.
Merlini PA, Rossi M, Menozzi A et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation, 2004; 109: 2203-2206.
Gore JM, Spencer FA, Gurfinkel EP et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol, 2009; 103: 175-180.
Vora AN, Chenier M, Schulte PJ et al. Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. Am Heart J, 2014; 168: 189-196, e181.
Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program, 2010; 2010: 135-143.
Warkentin TE. Drug-induced immune-mediated thrombocytopenia - from purpura to thrombosis. N Engl J Med, 2007; 356: 891-893.
Dasgupta H, Blankenship JC, Wood GC et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J, 2000; 140: 206-211.
Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J, 2010; 31: 35-49.
Tempelhof MW, Benzuly KH, Fintel D, Krichavsky MZ. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Tex Heart Inst J, 2012; 39: 86-91.
Arnold DM, Nazi I, Warkentin TE et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013; 27: 137-145.
McCullough J. Overview of platelet transfusion. Semin Hematol, 2010; 47: 235-242.
Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med, 2013; 368: 737-744.
Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med, 2001; 344: 1286-1292.
Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta, 2015; 1851: 422-432.
Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation, 2014; 129: 907-916.
Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet, 2013; 382: 769-779.
Devereaux PJ, Xavier D, Pogue J et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med, 2011; 154: 523-528.
Devereaux PJ, Chan MT, Alonso-Coello P et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA, 2012; 307: 2295-2304.
Chow CK, Jolly S, Rao-Melacini P et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation, 2010; 121: 750-758.
Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504.
A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA, 1982; 247: 1707-1714.
Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol, 1997; 29: 229-236.
Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003; 348: 1309-1321.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med, 1998; 339: 489-497.
Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681.
LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435.
Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-97.
Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342: 145-153.
Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559.
Bangalore S, Steg G, Deedwania P et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA, 2012; 308: 1340-1349.
Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J, 2013; 34: 2159-2219.
Piepoli MF, Corra U, Abreu A et al. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice. Int J Cardiol, 2015; 180: 114-119.
Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med, 2005; 143: 659-672.
Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA, 2003; 290: 86-97.
Iestra JA, Kromhout D, van der Schouw YT et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation, 2005; 112: 924-934.
Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003; 362: 782-788.
Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998; 351: 1755-1762.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998; 317: 703-713.
Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med, 2004; 116: 682-692.
Taylor RS, Unal B, Critchley JA, Capewell S. Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements? Eur J Cardiovasc Prev Rehabil, 2006; 13: 369-374.
Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation, 2010; 121: 63-70.
Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012; 33: 1635-1701.
Heran BS, Chen JM, Ebrahim S et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev, 2011; 1: CD001800.
Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol, 2013; 20: 620-640.
Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target, 140 mm Hg indicated in all hypertensives? Subgroup analyses of findings from the randomized fever trial. Eur Heart, 2011; 32: 1500-1508.
Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet, 2004; 364: 849-857.
Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens, 2009; 27: 923-934.
Nallamothu B, Fox KA, Kennelly BM et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart, 2007; 93: 1552-1555.
Mukherjee D, Fang J, Chetcuti S et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation, 2004; 109: 745-749.
